Since 2010, there have been 19 approvals by the U.S. Food and Drug Administration, or FDA, for the treatment of pain, of which 11 were opioid variants, one was an extended release generic corticosteroid, five were variants of aspirin, and two were variants of other existing drugs.

In the area of neurological disorders, cannabis-based medicines have demonstrated safety, efficacy, and consistency sufficient for regulatory approval in multiple sclerosis and in rare forms of epilepsy, approved for these indications by the FDA in June 2018. Recently, positive developments using cannabinoids in a variety of difficult-to-treat neurological disorders have offered a significant and promising pathway to potential breakthroughs in the healthcare industry.

FSD is developing a portfolio of novel cannabinoid drug candidates designed to overcome the limitations of current treatment options for chronic pain and to present patients and physicians with better and safer treatment alternatives.

Research Areas

FSD’s research and development platform is focused on medical cannabinoids and their potential for widespread clinical applications. The company places high value on strategic partnerships with companies and organizations whose strengths, experience and knowledge complement our own. We are constantly evaluating collaborations with leading academic institutions and companies to develop innovative solutions.

At FSD, our strategy is to make investments and to create alliances with companies and academic institutions to bring medicines to patients who need them.

Prismic Pharmaceuticals

Prismic Pharmaceuticals was acquired by FSD Pharma in June 2019. Prismic is a US-based specialty pharmaceutical company dedicated to addressing the opioid crisis by developing novel non-addictive prescription drugs for the treatment of pain, inflammation, and neurological disorders.

Learn More »

Strategic partnerships

Cannara Biotech
Strategic Investment
Montreal, QC

FSD invested in Cannara Biotech, which plans to be the largest indoor cultivation facility in Quebec. Cannara purchased a modern 625,000 sq. ft. facility on 27 acres of land, located less than one-hour drive from Montreal. FSD has an equity investment of 85,003,750 Class B shares of Cannara.

CannTab Therapeutics
Collaboration and Profit Sharing Agreement
Markham, Canada

Canntab Therapeutics was founded on April 20, 2016 by pharmaceutical industry professionals who saw an urgent need to add industry rigor and professionalism to the medicinal cannabis market. CannTab is the first company solely dedicated to research and development of oral dosage therapeutic formulations of cannabis. The company developed a unique, patent pending technology which resulted in the creation of a range of oral dosage products that effectively treat different ailments by delivering a uniform dosage of medicinal cannabis extract.

SciCann Therapeutics
Strategic Partnership
Tel Aviv, Israel

SciCann Therapeutics is a Canadian-Israeli specialty pharmaceutical company, dedicated to the development and commercialization of novel and disruptive pharmaceutical products that target and modulate the endocannabinoid system.

SciCann Therapeutics is active in the fields of oncology, pain management, neurodegenerative diseases and inflammatory disorders, and develops a line of proprietary products for the treatment of chosen life-threatening conditions that present a high level of unmet need.

High Tide Inc.
Strategic Investment
Alberta + Saskatchewan

High Tide is an Alberta-based, downstream cannabis corporation focused on the manufacturing and wholesale distribution of smoking accessories and cannabis lifestyle products. It is a vertically-integrated company in the Canadian cannabis market, with portfolio subsidiaries including RGR Canada Inc., Famous Branz Inc., Kush West Distribution Inc., Smoker’s Corner Ltd.,, Canna Cabana Inc., and the majority of Kush Bar Inc. High Tide’s strategy as a parent company is to extend and strengthen its integrated value chain, while providing a complete customer experience and maximizing shareholder value.

World-Class Extractions
Collaboration and License Agreement
Toronto, Canada

World-Class Extractions provides precision single step mobile extraction services using patent pending technologies that produce higher yields of crude at faster rates. World-Class Extractions can save its clients floor space, process fees, utility fees, equipment cost and more, including minimizing by-product plant biomass produced and materials used in extraction recovery.

Collaborative Research Agreement

FSD has signed a LOI with Solarvest to develop and test pharma-grade cannabinoids out of algae. The Pharma Grade process could reduce the production time for targeted cannabinoid molecule(s) by up to 95%. Solarvest is an algae technology company whose production platform provides it with an extremely flexible system capable of being adapted to produce numerous products. The Company has completed a feasibility study for the expression of CBD and THC as a way to produce cannabinoids in sterile GMP facilities.

Retail Shops

Huge Shops
Toronto, Ontario

FSD completed a strategic investment in Huge Shops, a Toronto-based cannabis retailer. Huge Shops has a strategic alliance with Chairman’s Brands, parent company of Coffee Time, a well-established operator of retail coffee shops with more than 75 locations in Canada and other locations worldwide.

As part of the investment, Huge Shops has the option to acquire a minimum of ten retail locations under Chairman’s umbrella of properties, and, subject to availability and further negotiation, purchase additional Coffee Time sites.

FSD’s investment in Huge Shops’ will enable us to quickly create a network, with a well-established consumer base of 14 million consumers, in key demographic areas throughout Ontario.

Financial Partners

First Republic Capital
Strategic Alliance
Toronto, Canada

First Republic Capital focuses on public Canadian and US micro-cap companies. Clients receive more than just financing – they get a dedicated investment banking partner with the responsiveness, credibility and capability to help them achieve their market goals. First Capital partners with their clients and supports them over time as their business and capital structure evolves and provides aftermarket support.